Neurocrine Biosciences, Inc. (NBIX) News
Filter NBIX News Items
NBIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBIX News Highlights
- 500 - Internal server error
- Over the past 21 days, the trend for NBIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about NBIX are SA.
Latest NBIX News From Around the Web
Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.
Subdued Growth No Barrier To Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) PriceWith a price-to-earnings (or "P/E") ratio of 23.4x Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) may be sending bearish... |
Idorsia: Putting The Capstone On A Foundationally Strong Biotecheakrin rasadonyindee/iStock via Getty Images On July 16th, 2019, I shared an article here on SA-" A Swiss Biotech Poised For Fantastic Growth". At the time I wrote this first article about Idorsia (OTCPK:IDRSF) I pointed out that I had identified the potential in the company back in December 2018.... |
Hematuria Treatment Market 2028 Analysis of Key Players Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx PharmaceuticalsA new market report by The Insight Partners on the Hematuria Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of |
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceNeurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference. |
Neurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day BasisOf note is that the 100 day changed directions on nbix; it is now pointing up. The post Neurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News . |
OBSV Stock: The Big Clinical Trial News Boosting ObsEva TodaySwiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. |
Polycystic Ovary Syndrome Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Dexa Medica, Astellas, EffRx, Spruce Biosciences, Neurocrine Biosciences and OthersNo summary available. |
Texas Permanent School Fund Buys Shares of 70,180 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Texas Permanent School Fund bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 70,180 shares of the companys stock, valued at approximately $6,825,000. Texas Permanent School Fund owned 0.07% [] |
Strs Ohio Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Strs Ohio lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 59.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,214 shares of the companys stock after selling 13,343 shares during the period. Strs Ohios holdings in [] |
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare ConferenceSAN DIEGO , May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021 . Matt Abernethy , Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will |